Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis

Clinical Infectious Diseases

Volumn 39, Issue 12, 2004, Pages 1754-1760

  Watkins Riedel, Thomas ^a,b,f   Ferenci, Peter ^c   Steindl Munda, Petra ^c   Gschwantler, Michael ^d   Mueller, Christian ^c   Woegerbauer, Markus ^d,e  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

^e Wilhelminenspital Hospital of Vienna ^*  (Austria)

^f WILHELMINEN HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; MALE; MIDDLE AGED; RECURRENCE; RNA, VIRAL;

EID: 10644231765     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/425614     Document Type: Article

References (30)

1. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-92.
2. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of Interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus Interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998; 352:1426-32.
3. EASL International Consensus Conference on Hepatitis C. Consensus statement. J Hepatol 1999; 30:956-61.
4. Management of hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19:1-46.
5. Bouffard P, Hayashi PH, Acevedo R, Levy N, Zeldis JB. Hepatitis C virus is detected in a monocyte/macrophage subpopulation of peripheral blood mononuclear cells of infected patients. J Infect Dis 1992; 166:1276-80.
6. Wang JT, Shen JC, Lin JT, Wang TH, Chen DS. Detection of a replicative form of hepatitis C virus RNA in peripheral blood mononuclear cells. J Infect Dis 1992; 166:1167-9.
7. Oesterreicher C, Hammer J, Koch U, et al. HBV and HCV genome in peripheral blood mononuclear cells in patients undergoing chronic hemodialysis. Kidney Int 1995; 48:1967-71.
8. Laskus T, Radkowski M, Piasek A, et al. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 2000; 181:442-8.
9. Morita T, Hada H, Koide N, et al. Detection of hepatitis C virus RNA in circulating immune complexes by RT-PCR. Hepatogastroenterology 1996; 43:582-5.
10. Manzin A, Solforosi L, Candela M, et al. Hepatitis C virus infection and mixed cryoglobulinaemia: assessment of HCV RNA copy numbers in supernatant, cryoprecipitate and non-liver cells. J Viral Hepat 1996; 3:285-92.
11. Schmidt WN, Stapleton JT, LaBrecque DR, et al. Hepatitis C infection and cryoglobulinemia: analysis of whole blood and plasma HCV RNA concentration and correlation with liver histology. Hepatology 2000; 31:737-44.
12. Schmidt W, Klinzman D, LaBrecque D, Macfarlane D, Stapleton J. Direct detection of hepatitis C virus (HCV) RNA from whole blood, and comparison with HCV RNA in plasma and peripheral blood nuclear cells. J Med Virol 1995; 47:153-60.
13. Schmidt W, Wu P, Han J, Perino M, LaBrecque D, Stapleton J. Distribution of hepatitis C virus (HCV) RNA in whole blood and blood cell fractions: plasma HCV RNA analysis underestimates circulating virus load. J Infect Dis 1997; 176:20-6.
14. Schmidt WN, Wu P, Cederna J, Mitros FA, LaBrecque DR, Stapleton JT. Surreptitious hepatitis C virus (HCV) infection detected in the majority of patients with cryptogenic chronic hepatitis and negative HCV antibody tests. J Infect Dis 1997; 176:27-33.
15. Schmidt WN, Wu P, Brashear D, et al. Effect of interferon therapy on hepatitis C virus RNA in whole blood, plasma, and peripheral blood mononuclear cells. Hepatology 1998; 28:1110-6.
16. Muratori L, Giostra F, Cataleta M, et al. Testing for hepatitis C virus sequences in peripheral blood mononuclear cells of patients with chronic hepatitis C in the absence of serum hepatitis virus RNA. Liver 1994; 14: 124-8.
17. Stapleton JT, Klinzman D, Schmidt WN, et al. Prospective comparison of whole-blood- and plasma-based hepatitis C virus RNA detection systems: improved detection using whole blood as the source of viral RNA. J Clin Microbiol 1999; 37:484-9.
18. Cook L, Ross AM, Knight GB, Agnello V. Use of whole blood specimens for routine clinical quantitation of hepatitis C virus RNA does not increase assay sensitivity. J Clin Microbiol 2000; 38:4326-31.
19. Young KKY, Resnick RM, Myers TW. Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol 1993; 31:882-6.
20. Lee SC, Antony A, Lee N, et al. Improved version 2.0 qualitative and quantitative Amplicor reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 2000; 38:4171-9.
21. Hendricks DA, Friesenhahn M, Tanimoto L, Goergen B, Dodge D, Comanor L. Multicenter evaluation of the Versant HCV RNA qualitative assay for detection of hepatitis C virus RNA. J Clin Microbiol 2003; 41:651-6.
22. Ferenci P, Stauber R, Steindl-Munda P, et al. Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon-α in interferon nonresponders with chronic hepatitis C. J Viral Hepat 1999; 6:53-8.
23. Ferenci P, Stauber R, Steindl-Munda P, et al. Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon α with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group. Eur J Gastroenterol Hepatol 2001; 13:699-705.
24. Manavi M, Baghestanian M, Watkins-Riedel T, et al. Detection of hepatitis C virus (HCV) RNA in normal cervical smears of HCV-seropositive patients. Clin Infect Dis 2002; 35:966-73.
25. Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000; 32:654-9.
26. Schroeter M, Zoellner B, Schaefer P, Laufs R, Feucht H-H. Quantitative detection of hepatitis C virus RNA by LightCycler PCR and comparison with two different PCR assays. J Clin Microbiol 2001; 39:765-8.
27. Watkins-Riedel T, Woegerbauer M, Hollemann D, Hufnagl P. Rapid diagnosis of enterovirus infections by real-time PCR on the LightCycler using the TaqMan format. Diagn Microbiol Infect Dis 2002; 42:99-105.
28. Jessner W, Gschwantler M, Steindl-Munda P, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001; 358:1241-2.
29. Kono Y, Hayashida K, Tanaka H, Ishibashi H, Harada M. High-density lipoprotein binding rate differs greatly between genotypes 1b and 2a/ 2b of hepatitis C virus. J Med Virol 2003; 70:42-8.
30. Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to the polymerase chain reaction based assays. Hepatology 2000; 32:818-23.